Vaccines
Shares of Moderna are down nearly 10% this morning despite the company posting positive interim results from an experimental seasonal flu vaccine.
Pfizer and BioNTech reported laboratory assays indicating that three doses of their mRNA COVID-19 vaccine are effective against the new COVID-19 variant, Omicron.
Scientists from Cardiff University and the Arizona State University believe they have found the likely cause of blood clotting in some recipients of the Oxford-AstraZeneca COVID-19 vaccine.
It was recently announced that a low dose of the Pfizer-BioNTech vaccine is safe for kids ages 5 to 11.
IDRI is working with a newly-formed consortium to develop a next-gen COVID-19 vaccine that will be stable at routine temperatures and that may be able to confer immunity for a longer duration.
Four BMS employees have filed a lawsuit against BMS after claiming the company would not grant them a religious exemption and threatened their employment.
The FDA’s decision is based on positive results from two Phase III trials, the PROTECT and CONSTANT, on the drug’s efficacy.
The takeover is part of the French biotech giant’s “Play to Win” strategy of growing its global vaccines pipeline through the acquisition of promising projects and companies.
Pfizer veteran Phil Dormitzer will assume the role of Global Head of Vaccines beginning Friday.
Omicron has caused the U.S. to install travel bans against several South African countries while vaccine makers rush to test their vaccines against it. For that news and more, continue reading.
PRESS RELEASES